Astellas Pharma's EBIT per Share for the
three
months ended in Mar. 2026 was $0.18.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.44.
During the past 12 months, the average EBIT per Share Growth Rate of Astellas Pharma was 844.30% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 43.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -0.20% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -10.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Astellas Pharma's EBIT per Share or its related term are showing as below:
ALPMF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -51.1 Med: 2.4 Max: 80.6
Current: 43.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Astellas Pharma was 80.60% per year. The lowest was -51.10% per year. And the median was 2.40% per year.
ALPMF's 3-Year EBIT Growth Rate is ranked better than 85.8% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs ALPMF: 43.20
Astellas Pharma's EBIT for the
three
months ended in Mar. 2026 was $322 Mil.
Astellas Pharma (OTCPK:ALPMF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Astellas Pharma EBIT per Share Related Terms
Astellas Pharma EBIT per Share Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.44
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astellas Pharma (ALPMF) has a EBIT per Share of $1.44 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Astellas Pharma and its competitors. According to the industry distribution chart, Astellas Pharma ranks #115 out of 810 companies in the Drug Manufacturers industry, placing it in the top 14.2%.
Is Astellas Pharma's EBIT per Share too high?
Astellas Pharma's current EBIT per Share is $1.44. The Drug Manufacturers industry median EBIT per Share is 7.65. Astellas Pharma's value of $1.44 is 81.2% below this industry median. Based on the distribution chart, Astellas Pharma ranks #115 out of 810 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's EBIT per Share compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #115 out of 810 companies for EBIT per Share. This places Astellas Pharma in the top 14% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.65. Astellas Pharma's value of $1.44 is 81.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current EBIT per Share of $1.44 is 81.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current EBIT per Share is $1.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Modestly Undervalued. The stock's GF Value™ is $14.80, compared to a current price of $13.15 — trading 11.1% below its estimated fair value. The current EBIT per Share is $1.44 and 81.2% below the Drug Manufacturers industry median of 7.65. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current EBIT per Share is $1.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $13.15 is trading 11.1% below its estimated GF Value™ of $14.80.
GuruFocus considers Astellas Pharma to be Modestly Undervalued.
Key valuation signals for ALPMF:
EBIT per Share: $1.44
GF Value™: $14.80 vs. price of $13.15 (11.1% below fair value)
Industry Position: 81.2% below the Drug Manufacturers median (#115 of 810)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score
Get the complete analysis for ALPMF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
